ICU Medical, Inc. — Q1 2018 Form 10-Q
Reporting period: Three months ended March 31, 2018. Amounts below are in U.S. dollars; financial statement figures are converted from thousands to millions unless noted.
Business context and reporting period
ICU Medical develops, manufactures and sells medical devices and products for infusion therapy and critical care. Its four main product lines are Infusion Consumables, IV Solutions, Infusion Systems and Critical Care. The quarter reflects the continuing integration of Pfizer’s Hospira Infusion Systems (HIS) business, acquired in February 2017. The comparison is not fully like-for-like: Q1 2017 included about two months of HIS revenue after closing, while Q1 2018 included a full quarter. Revenue presentation also changed with adoption of ASC 606 on January 1, 2018; prior periods were not restated.
Financial results and liquidity
| Metric | Q1 2018 | Q1 2017 |
|---|---|---|
| Total revenue | $372.0 million | $247.7 million |
| Gross profit / gross margin | $149.0 million / 40.1% | $88.9 million / 35.9% |
| Operating income (loss) | $2.9 million | $(17.0) million |
| Net income | $4.9 million | $55.9 million |
| Diluted earnings per share | $0.23 | $2.86 |
| Cash from operating activities | $(20.7) million | $(76.6) million |
| Cash from investing activities | $(15.0) million | $(173.9) million |
Revenue rose about 50%. By product line, Q1 2018 revenue was $119.9 million from Infusion Consumables, $144.4 million from IV Solutions, $93.4 million from Infusion Systems and $14.2 million from Critical Care. Management attributed growth largely to the HIS acquisition comparison; IV Solutions also benefited from increased demand amid market shortages. Gross margin improved partly because Q1 2017 included purchase-accounting inventory step-up costs.
Q1 2018 operating expenses included $21.6 million of restructuring, strategic transaction and integration costs, a $28.9 million product-partner contract settlement charge, and a $4.0 million gain from reducing the fair value of the Pfizer earn-out liability. The 2017 comparison included a $63.2 million bargain-purchase gain. These items, along with acquisition timing, make year-over-year net income comparisons particularly uneven. The 2018 tax benefit included discrete benefits of $5.7 million related to the settlement and $3.4 million from equity compensation tax benefits.
At March 31, 2018, cash and cash equivalents were $254.5 million and investment securities were $24.1 million, totaling $278.6 million, down from $314.7 million at December 31, 2017. Current assets were $868.5 million and current liabilities were $198.6 million. Related-party receivables, principally amounts due from Pfizer, were $132.3 million. The company had no borrowings under its $150 million revolving credit facility, which matures in 2022, and reported compliance with its covenants. The $75 million Pfizer seller note had been repaid by year-end 2017.
Operating cash use reflected working-capital outflows, including higher related-party and trade receivables and payment of accrued compensation. Capital expenditures were $26.5 million in Q1; management estimated full-year 2018 capital expenditures of approximately $70 million. The filing states that existing cash and expected operating cash generation should fund operations for the next twelve months. No quarterly or full-year earnings guidance is provided.
Material changes, outlook and risks
- Revenue accounting: ASC 606 adoption increased opening retained earnings by $6.3 million. For Q1, reported revenue was $2.0 million lower than it would have been without adoption. Remaining performance obligations included $7.6 million related to equipment and software implementation, expected substantially within six months, and $4.2 million of annual software licenses, expected substantially within twelve months.
- Integration and restructuring: HIS-related transaction and integration costs were $19.8 million in Q1. The company reported cumulative HIS restructuring charges of $20.6 million and said all material charges for those activities had been incurred by March 31, 2018.
- Pfizer earn-out: Pfizer may receive up to $225 million in cash based on performance through December 31, 2019. The recorded fair-value liability was $23.0 million at March 31, 2018; the ultimate amount, if any, depends on performance targets.
- Legal and regulatory matters: The filing describes saline-solution antitrust litigation and related government inquiries, with indemnification claims between ICU Medical and Pfizer. In April 2018, the DOJ also issued a subpoena concerning Sapphire infusion pumps and related products. The filing does not quantify potential exposure.
- Foreign exchange: ICU Medical reported a net Euro asset position of approximately €83.3 million; a 10% exchange-rate change would affect the relevant consolidated balance-sheet amounts by about $10.3 million. The company said it does not hedge its Euro exposure, though it uses Mexico-peso cash-flow hedges.
- Commercial and execution risks: Management noted reliance on strategic customer, distributor and manufacturing relationships; customer ordering fluctuations; competitive pricing; integration and production challenges; and the possibility that growth investments may not deliver expected results. The company also said it may need alternative financing if operating performance or working-capital needs materially diverge from expectations.
Most important facts for investors to verify
- How much of reported revenue growth and margin improvement reflects underlying demand versus HIS acquisition timing, market shortages and accounting presentation changes.
- Whether integration costs, the $28.9 million settlement and other unusual items recur, and how they affect operating cash generation.
- Collection timing and recoverability of the $132.3 million related-party receivable from Pfizer.
- Potential outcomes and indemnification coverage for the saline antitrust matters and the DOJ Sapphire subpoena.
- Performance assumptions underlying the $23.0 million earn-out liability and possible cash payments up to $225 million.
- Execution of the approximately $70 million capital expenditure plan, liquidity needs and compliance with revolving-credit covenants.